Novartis Financials

Novartis Stock Summary

Novartis competes with Roche Holding, AstraZeneca PLC, Roche Holding, Sanofi ADR, and Bristol-Myers Squibb. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 104323 people.

Novartis Key Financial Ratios

There are many critical financial ratios that Novartis' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Novartis AG reports annually and quarterly.

Novartis Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Novartis's current stock value. Our valuation model uses many indicators to compare Novartis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novartis competition to find correlations between indicators driving Novartis's intrinsic value. More Info.Novartis AG is regarded second in return on equity category among its peers. It also is regarded second in return on asset category among its peers reporting about  0.59  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Novartis AG is roughly  1.69 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novartis' earnings, one of the primary drivers of an investment's value.

Novartis AG Systematic Risk

Along with financial statement analysis, the daily predictive indicators of Novartis help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Novartis AG. We use our internally-developed statistical techniques to arrive at the intrinsic value of Novartis AG based on widely used predictive technical indicators. In general, we focus on analyzing Novartis Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Novartis's daily price indicators and compare them against related drivers.

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.